Relapsed or Refractory Peripheral T/NK Cell or Cutaneous T Cell Lymphoma research hub

A Single-arm, Phase II Study to Evaluate the Efficacy and Safety of Linperlisib (YY-20394) Monotherapy in Patients with Relapsed or Refractory Peripheral T/NK Cell or Cutaneous T Cell Lymphoma

This study is testing a new drug called Linperlisib for people with specific types of T-cell lymphoma that have come back or not responded to previous treatments. It aims to see how well the drug works and if it's safe.